Long-Term Follow-Up of Combination Therapy with Sintilimab and Anlotinib in Gallbladder Follicular Dendritic Cell Sarcoma: A Rare Case Report

Abstract

Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm for which a standardized treatment approach has yet to be established. The prevailing therapeutic strategy typically involves resection followed by adjuvant chemotherapy or radiation. This case report details the long-term follow-up of a 59-year-old Chinese male diagnosed with gallbladder FDCS and liver metastases. The patient received a combination therapy of sintilimab and anlotinib, resulting in a substantial partial response (PR) lasting for a noteworthy duration of 30 months. Notably, this is the first documented instance of gallbladder FDCS with liver metastases being treated with PD-1 antibody and antiangiogenic agents as first-line therapy. These findings suggest that this treatment regimen may offer a potential therapeutic option for patients with gallbladder FDCS and liver metastases, with a duration of PR lasting up to 30 months.

Keywords:

• gallbladder follicular dendritic cell sarcoma
• long-term follow-up
• PD-1 antibody
• antiangiogenic agents
• first-line therapy
• partial response

Abbreviations

FDCS, follicular dendritic cell sarcoma; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; ICIs, immune checkpoint inhibitors; PR, partial response; FDG, fluorodeoxyglucose; NGS, next-generation sequencing; TMB, mutation tumors burden; MSI, microsatellite instability; PFS, progression-free survival.

Data Sharing Statement

All inquiries can be directed to the corresponding authors.

Ethics

The patient provided informed consent to publish their case details and any accompanying images. The studies involving human participants were reviewed and approved by the Institutional Review Board review (Approval number QT2023279) at Zhejiang Provincial People’s Hospital in Hangzhou, China. The patient provided their written informed consent to participate in this study.

Acknowledgments

The authors thank the patient and his family for their support.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This work was supported by Medical and Health Science and Technology Research Program of Zhejiang Province (2022KY061), Zhejiang Province Traditional Chinese Medicine Science and Technology Project (2023ZA015).